Sanofi will record a $1.0 billion research and development expense related to the Regeneron upfront payment in its Q3 2026 earnings release published by 31 October 2026.
Posted 2026-10-01 — 30 days before the deadline, stated before the outcome.
The claim
Sanofi will record a $1.0 billion research and development expense related to the Regeneron upfront payment in its Q3 2026 earnings release published by 31 October 2026.
Reasoning trace
- Sanofi and Regeneron announce expanded alliance with $1B upfront
- Sanofi commits to pay the upfront in Q3 2026
- Sanofi records the payment as an R&D expense in Q3 results
Evidence so far
2 confirming · 0 denying signals · 1 verified · 0 broken assumptions. The evidence itself is part of the full dossier.
Probability history
Updated 2 times since mint (last on 2026-10-02) — 78% at mint → 78% today.
What to watch
- leading indicator Sanofi announces a specific date for its Q3 2026 earnings call in a pre-announcement notice
- milestone Sanofi files its Q3 2026 Form 6-K with the SEC
- precondition Sanofi's Q3 2026 cash flow statement shows a cash outflow of approximately $1.0 billion categorized under 'Payments for research and development' or 'Other operating activities' related to the Regeneron alliance
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.